Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Flexibility: Four Strategies for the Future

This article was originally published in RPM Report

You may also be interested in...



An Eye for an Eye: Lucentis and the New Pharmaceutical Value System

A head- to- head trial of Genentech’s Avastin v. Lucentis raises the stakes in the debate over drug pricing. While previous large comparative trials have focused on a number of different drugs--old against new--the Avastin study is evaluating two brand new cutting edge technologies, one for off-label use. Genentech is not alone in finding this unsettling.

Show Me the Value

As cancer drug prices approach $100,000, manufacturers are facing strong resistance from manufacturers. Now Wall Street is starting to worry.

Show Me the Value

As cancer drug prices approach $100,000, manufacturers are facing strong resistance from manufacturers. Now Wall Street is starting to worry.

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel